Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.

Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG.

Psychopharmacology (Berl). 1982;76(3):245-50.

PMID:
6285406
2.

Cannabinoids in clinical practice.

Williamson EM, Evans FJ.

Drugs. 2000 Dec;60(6):1303-14. Review.

PMID:
11152013
3.

Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.

Ashton CH, Moore PB, Gallagher P, Young AH.

J Psychopharmacol. 2005 May;19(3):293-300. Review.

PMID:
15888515
4.

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D.

Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Review.

5.

Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.

Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK.

Curr Pharm Des. 2012;18(32):4966-79. Review.

PMID:
22716148
6.
7.

Cannabidiol as potential anticancer drug.

Massi P, Solinas M, Cinquina V, Parolaro D.

Br J Clin Pharmacol. 2013 Feb;75(2):303-12. doi: 10.1111/j.1365-2125.2012.04298.x. Review.

8.

Endocannabinoid system dysfunction in mood and related disorders.

Ashton CH, Moore PB.

Acta Psychiatr Scand. 2011 Oct;124(4):250-61. doi: 10.1111/j.1600-0447.2011.01687.x. Review.

PMID:
21916860
9.

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS.

Curr Pharm Des. 2012;18(32):5131-40. Review.

PMID:
22716160
10.
11.

Cancer cachexia and cannabinoids.

Gorter RW.

Forsch Komplementarmed. 1999 Oct;6 Suppl 3:21-2. Review.

PMID:
10575285
12.

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW.

Rev Bras Psiquiatr. 2012 Jun;34 Suppl 1:S104-10. Review. English, Portuguese.

13.
14.

Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.

Burstein S.

Bioorg Med Chem. 2015 Apr 1;23(7):1377-85. doi: 10.1016/j.bmc.2015.01.059. Review.

PMID:
25703248
15.

Does Cannabidiol Protect Against Adverse Psychological Effects of THC?

Niesink RJ, van Laar MW.

Front Psychiatry. 2013 Oct 16;4:130. doi: 10.3389/fpsyt.2013.00130. Review.

16.

Interactions of cannabis with other drugs in man.

Hollister LE.

NIDA Res Monogr. 1986;68:110-6. Review.

PMID:
3095648
17.

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.

de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, Machado S, Arias-Carrión O, Crippa JA, Zuardi AW, Nardi AE, Silva AC.

CNS Neurol Disord Drug Targets. 2014;13(6):953-60. Review.

PMID:
24923339
18.

Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.

Fasinu PS, Phillips S, ElSohly MA, Walker LA.

Pharmacotherapy. 2016 Jul;36(7):781-96. doi: 10.1002/phar.1780. Review.

PMID:
27285147
19.

Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.

Hayakawa K, Mishima K, Fujiwara M.

Pharmaceuticals (Basel). 2010 Jul 8;3(7):2197-2212. Review.

20.
Items per page

Supplemental Content

Support Center